Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the best dose of venetoclax when given together with
azacitidine and pevonedistat and to see how well it works in treating patients with newly
diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of
cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Pevonedistat may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving azacitidine, venetoclax, and pevonedistat may work better in treating patients with
acute myeloid leukemia.